Harley-Davidson Inc vs Invesco Ltd. — how do they compare? Harley-Davidson Inc trades at $26.86 (market cap $2.78B), while Invesco Ltd. trades at $29.52 (market cap $13.28B). The key difference: Invesco Ltd. is far larger — about 4.8× Harley-Davidson Inc's market cap, and Invesco Ltd. pays the higher dividend (2.86%). Which is the better fit depends on your goals — on Pluang, investors hold Harley-Davidson Inc for 92 Days and Invesco Ltd. for 77 Days on average.
| HOG | IVZ | |
|---|---|---|
Market Cap | $2.78B | $13.28B |
Volume | 2,966,389 | 3,698,033 |
Sector | Consumer Cyclical | Financials |
52-Week High | $28.46 | $33.31 |
52-Week Low | $17.19 | $22.44 |
Typical Hold Time | 92 Days | 77 Days |
Enterprise Value | $3.20B | $23.45B |
Dividend Yield | 2.8% | 2.86% |
Signals from Pluang's Aura AI — not financial advice
Harley-Davidson (HOG) trades at $26.90, down 0.19% with mixed technical signals showing bullish moving averages but neutral oscillators. The company reported Q2 2026 earnings beat ($0.75 vs $0.645 expected) but missed Q1 expectations. Revenue has declined from $5.8B in 2022 to $4.5B in 2025, though valuation ratios remain attractive with P/E of 14.86 and P/S of 0.72. Recent news highlights tariff exposure and a data breach investigation.
The stock offers value with reasonable multiples but faces revenue headwinds and operational challenges. Analyst consensus is cautious with 61% hold ratings and $28.50 price target suggesting limited upside. Key risks include declining motorcycle demand, tariff sensitivity, and competitive pressures in the evolving auto industry.
Invesco (IVZ) trades at $29.51, down 3.25% today, with bearish technical signals dominating. The company reported mixed quarterly earnings, beating in Q4 2025 and Q2 2026 but missing in Q1 2026, while Q3 2026 results are pending. Despite negative net income margins in 2025, operating cash flow remains strong at $1.53 billion, and analyst consensus leans toward Hold with a $33.71 price target. Recent news highlights ETF expansions and AUM growth to $2.56 trillion in August 2026.
The outlook is cautious; IVZ faces profitability challenges with negative ROE and net margins, but solid cash flow and analyst buy ratings (42.86%) suggest recovery potential. Risks include earnings volatility and competitive ETF pressures, while institutional sentiment is neutral. The stock's current price near the low end of analyst targets ($28-$41) may appeal to value investors betting on operational improvements.
Trailing returns across standard periods
Latest headlines on both assets
Harley-Davidson is a global leading manufacturer of heavyweight motorcycles, merchandise, parts, and accessories. It sells custom, cruiser, and touring motorcycles and offers a complete line of Harley-Davidson motorcycle parts, accessories, riding gear, and apparel, as well as merchandise. Harley-Davidson Financial Services provides wholesale financing to dealers and retail financing and insurance brokerage services to customers. Harley has historically captured about half of all heavyweight domestic retail motorcycle registrations, a metric it had ceded in 2020 as it repositioned the business, but a level it is working back toward. In recent years the firm has expanded into the adventure touring market with its Pan America model and into electric with the LiveWire brand.
Read more on HOG →Invesco provides investment-management services to retail (65% of managed assets) and institutional (35%) clients. At the end of August 2022, the firm had $1.416 trillion in assets under management spread among its equity (47% of AUM), balanced (5%), fixed-income (22%), alternative investment (14%), and money market (12%) operations. Passive products account for 32% of Invesco's total AUM, including 56% of the company's equity operations and 13% of its fixed-income platform. Invesco's U.S. retail business is one of the 10 largest nonproprietary fund complexes in the country. The firm also has a meaningful presence outside the U.S., with close to one third of its AUM sourced from Canada (2%), the U.K. (4%), continental Europe (11%), and Asia (15%).
Read more on IVZ →